New approach methods (NAMs) continue to pave the way for more effective human risk assessments for FDA-regulated compounds. To help guide best approaches to these emerging methods, the FDA has released "Potential Approaches to Drive Future Integration of New Alternative Methods for Regulatory Decision-Making," the latest report detailing recommendations from a NAMs subcommittee of the FDA Science Board.

Improve your therapeutic efficacy predictions with our fully characterized patient-derived xenografts (PDX) representing multiple histotypes.

规划您的前进之路。下载药物研发流程图，全面了解未来发展。

如果您的业务目标是资产退出、投资或合作，可以在MarketPlace的帮助下启动战略对话。每月建立有效的联系。让我们为您提供下一次服务。

利用我们独特的集成程序化方法和专属项目经理，加速您的分子完成关键性里程碑，同时最大化您的资产价值。

通过遍布全球的实验室战略布局，我们具备为您的非临床和临床前研究提供全球支持的能力。